The colorectal cancer screening (CRC) projection test for blood vessels (FOBT) improves on women, especially men with tumors on the left, said researchers in Finland. Their effects come from a reorganization of a large analysis data.
The Finnish FOBT projection program (2004-2011) was made in more than 320,000 men between the ages of 60 and 69. Participants randomly handed and controlled weapons. The results of this test, published in 2015, differed from the difference between the two CRC death rates, compared to the discovery of randomly selected randomization sessions.
Dr. Laura Koskenvuo, a research team led by a gastrointestinal surgeon at the University Hospital in Helsinki, has analyzed data for evaluating results beyond "mortality".
The FOBT demonstrates every two years that it is "effective in improving human results, but not in women".
It was especially beneficial for tumors on the left side. In this sub-section, the FOBT projection has been a better overall survival, a lower rate of non-radical resistance and a need for post-operative chemotherapy.
However, these benefits were not seen in women, nor in the right side of the tumors.
The research was published on November 21 British Journal of Surgery.
The group suggests that the FOBT screening was not related to the improvement of female survival, "women should consider using different methods or through different stages or ages."
Completed FOBT examinations accounted for 41% of Finnish men and women by target age (60-69 years) at the end of 2011.
Although there was no significant difference between CRC mortality and control arm and arms, the results suggest a reduction in CRC death reduction among men and women. This finding has also been observed in other FOBT biennial studies, commented by the researchers.
"Koskenvu said at a press conference that he had almost no effect on the general cancer.
"However, they may still be useful in other ways. Patients could avoid liver treatments or not, even if they had been able to choose colon cancer," he explained.
The group therefore collected the CRC diagnostic data in the Finnish Cancer Registry and examined the medical records of the patients to identify the clinical and pathological TNM stages; Symptoms and surgery measure; The need for emergency surgical, stomach or chemotherapy for patients; and histopathological diagnoses.
In the study of 321,311 people, 743 CRC cases were detected in the arms, and 617 were detected in the control arm.
The study team patients are likely to continue to eliminate the entire tumor, do not need chemotherapy and no emergency surgery.
"Control groups account for 50% more emergency surgeries, 40% more non-healthy tumors and 20% more than treatment chemotherapy treatments," explained Ville Sallin, MD, PhD, guest lecturer at the University of Helsinki.
CRC was less common than in women, 0.34% and 0.50% (risk ratio) [RR], 0.82).
Women were not asymptomatic as men, 16.7% and 22.0 (RR, 0.76). Sabel was the only symptom of abdominal pain in male men (RR, 1.36).
Women may have the right side effects of men, 32.0% and 21.3% (RR, 1.51).
In the armed study, the T category of lower cancer (RR, 1.25), the N category (RR, 1.14) and the M category (RR, 1.33) were compared with the control arm.
Among men with tumors on the left side, on the patient's prescription arm, the type of cancer was lower in N (RR, 1.23) and M (RR, 1.57) than in control arms.
The men with tumors on the left side were more vigilant in arm control arm than 26.2% and 15.7% less (RR, 1.67) and postoperative chemotherapy, 61.6% 48.2 vs. (RR, 1.28).
Survival was worse on the control arm with CRC (men with a risky relationship) [HR], 1.31), but there was no difference between females [HR, 1.07].
Among men, 5-year survival rates were 68.8% in control arms at 61.5%. Among women, the rates were 70.7% and 71.5% respectively.
On the side of the tumor side, with tumors on the left side, survival was better than in the arms (HR, 1.37).
This benefit of survival was not compared to men with right-sided tumors, however (HR, 1.19)
. Survival rates were not affected by female tumors.
Coauthor Nea Malila, MD, PhD, director of the Finnish Cancer Registry in Helsinki, said the size of the sample is the strength of the study.
"Public health system has assigned a large number of people, which has allowed us to objectively evaluate the benefits of evidence," he said.
"Similar studies are not anywhere else," he said.
"In the future, we have to study the different operation techniques that can improve the patient's condition or improve the diagnosis of right-handed cancer of the colon," the researchers conclude.
Vatsatautien Tutkimussäätiö, the research fund at Helsinki University Hospital, funded by Mary and Georg Ehrnrooth Foundations, and the Cancer Foundation Finland. The authors have no financial relationship.
Br J Surg. Published online November 21, 2018. Full text
For more information about Medscape Oncology, follow us on Twitter: @MedscapeOnc